Cardiovascular

For each level of cardiovascular risk, lifestyle factors remain a significant contributor that can be modified to reduce risk. However, some risk will remain nonmodifiable and require therapy, according to panelists during a session on cardiovascular prevention at the European Society of Cardiology Congress 2017, held August 26-30 in Barcelona, Spain.

Rivaroxaban plus aspirin has significant benefits for patients with peripheral artery disease (PAD) and stable coronary artery disease, according to the results of the COMPASS (Cardiovascular OutcoMes for People using Anticoagulation StrategieS) trial, presented at the European Society of Cardiology Congress 2017, held August 26-30 in Barcelona, Spain.

Trial results that will be presented at the European Society of Cardiology Congress 2017 in Barcelona, Spain, will open up a new window into treatment for patients at risk of major cardiovascular events, explained Steven E. Nissen, MD, of Cleveland Clinic, at the start of the conference.

Novo Nordisk announced that its diabetes drug liraglutide (Victoza) has been approved by the FDA for a new indication: it can reduce the risk of major cardiovascular (CV) events in patients with type 2 diabetes (T2D) and existing CV disease.

The connection between diabetes and cardiovascular disease is well-known, but a new study gets at the mechanism of how this occurs.

The review reports that fewer than 50% of patients with diabetes are being treated according guidelines to prevent a cardiovascular event.

Patients with congenital heart defects, such as Marfan syndrome (MFS), are experiencing longer life expectancies due to new advances in medicine-resulting in a greater need for medical rehabilitation.

The reduced mortality risk was not seen in patients who did not have diabetes before surgery. But in those who did, the results were dramatic.

Patients often stop statin treatment following an adverse reaction; however, new research finds an association between continued statin prescriptions after an adverse reaction and a decreased incidence of death and cardiovascular events.

Many accountable care organizations participating in the Medicare Shared Savings Program focus on disease control and medication use, but a new study published in JAMA Cardiology has found that the programs have not made any meaningful changes in medication use or adherence.

Coverage from the first of 3 Peer Exchangeâ„¢ discussions from the Diabetes Stakeholders Summit.

There is an association between the presence of cardiovascular risk factors in adolescence and a lower cognition later in life, regardless of the exposure experienced during adulthood.

A new vaccine may be able to reduce low-density lipoprotein (LDL) cholesterol and, therefore, protect people against the risk of cardiovascular disease.

New results from a meta-analysis reveal a decrease in the excess risk of cardiovascular events in patients with rheumatoid arthritis (RA) since the start of the 21st century.

Liraglutide, a GLP-1 receptor agonist sold as Victoza, becomes the second diabetes therapy to receive the cardiovascular indication.

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

Cardiovascular outcomes trials and a photography ban that dominated social media were big news at the 77th Scientific Sessions of the American Diabetes Association.

The study's lead author said that complications from cardiovascular disease remain an unmet clinical challenge in type 2 diabetes.

While statins are primarily used to lower cholesterol, they are also associated with improved heart structure and function, according to research presented at EuroCMR 2017, which was held by the European Society of Cardiology, May 25-27, in Prague, Czech Republic.

Patients with peripheral artery disease can now have supervised exercise therapy covered by Medicare, according to a recent announcement by CMS.

While regulators long ago saw enough cardiovascular safety data to approve insulin degludec, full trial results will be presented June 12 at the American Diabetes Association Scientific Sessions in San Diego.